TAN | LAB A REVIEW OF 2015 http://tanlab.ucdenver.edu

Dear Colleagues and Friends,

As 2015 draws to a close, we should take time to reflect on the accomplishments of the past year and look to the opportunities ahead of us. The **Tan Lab** has much to celebrate in 2015.

Personnel: We welcome **Jennifer Hintzsche** (Jan 2015) and **Brian Jackson** (May 2015) as new post-doctoral research fellows in our lab. Jenn and Brian will be focusing on melanoma and head and neck cancer genomics, respectively. We hosted two visiting Ph.D. students from Prof. **Jaewoo Kang**'s lab at Korea University, **Kyubum Lee** (Aug 2014 – Feb 2015) and **Minji Jeon** (Mar 2015 – Aug 2015). Kyubum is developing new computational tools and resources to extract gene-variant-disease relations from full-text publications. Minji is devising new bioinformatics methods to predict drug responses from multiple omics data. We also hosted two Cancer Center Summer Fellows, **Harrison Pielke-Lombardo** (Applied Mathematics, University of Colorado-Boulder) and **Ryan Hays** (Computational Biology, Massachusetts Institute of Technology), in our lab. We also have the opportunity to host Prof. **Dong-Hoon Shin** (Oct 2014 – June 2015) from the Seoul National University while he is doing his sabbatical leave in learning bioinformatics in our lab.



Tan Lab (Summer 2015): Back (L-R): Brian, Jenn and Karen. Middle (L-R): Minjae, Ryan and Harrison. Front (L-R): Jihye, Minji, Jimin and AC.



Tan Lab Poster 2015.

Research: We continued to participate in and contribute to several high impact cancer research projects. In collaboration with the **PETT** lab members (**Eckhardt**, **Pitts**, **Tentler**, **Leong**, **Lieu**), we performed genome-wide synthetic lethality screens to identify rational combination partner with Selumetinib in KRAS-mutant colorectal cancer (CRC). Using a novel bioinformatics platform BiNGS! (developed by **Jihye** and **AC**) for the analysis of synthetic lethal screens together with integrating the results with unbiased gene set enrichment analysis, we unraveled the non-canonical Wnt/Ca++

signaling pathway as a potential mediator of resistance to Selumetinib. This key finding led to an evaluation of the rational combination of selumetinib and WNT pathway modulators (cyclosporin A) and demonstrated syneroistic antiproliferative effects in in vitro and in vivo models of CRC. Importantly, this combination not only showed tumor growth inhibition but also tumor regression in the more clinically relevant patient-derived tumor xenograft (PDX) models of KRAS-mutant CRC. These results strengthen the hypothesis that targeting both the MEK and Wnt pathways may be a clinically effective rational combination strategy for patients with metastatic CRC. More importantly, this study has now translated into a Phase I/IB clinical trial as an Investigator Initiated Trial at the University of Colorado Cancer Center Clinic (clinicaltrials.gov#: NCT02188264).

					Example: "Heart attai	ok" AND "LI	pa /richt-	Search	0
					Examp		Ton	c Glossary	6
			Search f	or studies:	Advanced Search	Help 5	studies by 10p		- I -
It in alTrials	gov				Hatte				
linicut I rationa	Institutes of Health	1		About	This Site			Text Size	- 1
service of the 0.3. rest		Submit Studies	Resources					1800 Dire	· 1
Abou	t Clinical Studies	guunn							1
Find Studies	- Datal				Adv	anced	or Metastat	IIC .	1
Find Studies > St	udy Record Desire			d Solid	Tumors or Au	a			- 1
Home	10	Treating Patients	With Auvante						
a lumotinib and Cy	closporine in				(and the second s				1
Colorectal Cancer			(Lengtions)	Clinical	Trials-gov Identities				
Contract	and antici	ipants. (see Contacts at	nd Location	NCTO	2186204	4			
This study is currently	ly recruiting parties	in de (NCI)		First re	ceived: July 10, 201	, 2015			
Fred October 2015 b	y National Cancer Int	filling to the second s		Last up	pdated: Actober 201	5			
Version -				Last	v of Changes				
Sponsor:	stitute (NCI)			A material					
Nanousia	by (Responsible Pr	arty):				broost			
10000									
Information provided	itute (NCI)		Discial	ner Elt	How to Head a start				
Information provided National Cancer Inst	itute (NCI)	No Study Results Po	sted Disclair	mer 🖬 H	How to Read a deal				
Information provided National Cancer Inst Full Text View	tute (NCI) Tabular View	No Study Results Po	sted Disclair	mer El H	fow to Read a creat				iorectal
Information previded National Cancer Inst Full Text View	tute (NCI) Tabular View	No Study Results Po	sted Disclair	mer 🖬 H	tow to Read a deal	mating pa	tients with solid	tumors or of	slorectal blocking
Information previded National Cancer Inst Full Text View	Tabular View	No Study Results Po	bubes over	n together v	with cyclosporine in t	treating pa may stop	tients with solid the growth of th	i tumors or or umor cells by nav stimulate	slorectal blocking or
Full Text View	Tabular View	No Study Results Po	metinib when gives	n together v	with cyclosporine in t atment. Seiumetinib	treating pa may stop 1 m living of	tients with solid the growth of the ganisms that if the a better treat	tumors or or umor cells by nay stimulate atment for sol	blorectal blocking or id tumors
Full Text View Purpose This phase Vib trial s	tudies the side effect	No Study Results Po	metinib when gives a cured or controll s, such as cyclospi	n together v led with treat orine, use s	Not to Read a contract with cyclosporine in t atment. Selumetinib substances made fro metinib and cyclosp	treating pa may stop t m living of orine may	tients with solid the growth of th ganisms that r be a better trea	i tumors or or imor cells by nay stimulate stiment for sol	slorectal blocking or id tumors
Information previded National Cancer Inst Full Text View Purpose This phase Vib trial s cancer that have spo	tudies the side effect ead to other places e needed for cell gri	No Study Results Po bis and best dose of selur in the body and cannot b owth. Biological therapies	metinib when given the curred or controll s, such as cyclospi ells from growing. I	n together v led with treat orine, use s Giving setu	Now to Read a decem with cyclosporine in t atment. Selumetinib substances made fro metinib and cyclosp	treating pa may stop t m living of orine may	tients with solid the growth of th ganisms that r be a better trea	i tumors or or imor cells by nay stimulate atment for sol	slorectal blocking or id tumors
Information previded National Cancer Inst Full Text View Purpose This phase l/lb trial st cancer that have sp some of the enzyme	tudies the side effect ead to other places is needed for cell gn e system in differen	No Study Results Po of and best dose of selur in the body and cannot b owth. Biological therapies it ways and stop tumor or	metinib when given the cured or controll s, such as cyclospi ells from growing. I	n together v ied with treat orine, use s Giving selu	Now to Read a development of the second seco	treating pa may stop t on living of orine may	tients with solid the growth of the ganisms that in be a better treat Phase	i tumors or or umor cells by nay stimulate atment for sol	slorectal blocking or id tumors
Information provided National Cancer Inst Full Text View Purpose This phase Vib Inal cancer that have spn some of the enzyme suppress the immune	tudies the side effected to other places s needed for cell gn es system in different.	No Study Results Po ots and best dose of seluri in the body and cannot b owth. Biological therapiet it ways and stop turnor or	metinib when given e cured or controll s, such as cyclospi elibs from growing. I	n together v led with trea giving selu	Now to Read a decement of the second se	treating pa may stop t m living of orine may	tients with solid the growth of th ganisms that n be a better trei Phase Phase	t tumors or or umor cells by nay stimulate atment for sol	slorectal blocking or id tumors
Hernwation provided National Cancer Inst Full Text View Purpose This phase Ufb that as score of the enzyme suppress the immun or colorectal cancer	Tabular View Tubies the side effected to other places is needed for cell gri to system in different.	No Study Results Po of and best dose of selut in the body and cannot b owth, Biological therapies it ways and stop tumor of	netinib when gives e cured or controll s, such as cyclospi ells from growing.	n together v led with trea orine, use s Giving setu	Nuth cyclosporine in 1 atment. Selumetinib substances made fro metinib and cyclosp	treating pa may stop 1 im living or orine may	tients with solid the growth of th ganisms that n be a better treat Phase Phase	i tumors or co unor cells by nay stimulate atment for sol	blorectal blocking or id tumons
Full Text View Full Text Full Text Full Full Full Full Full Full Full Full	Tabular View Tabular View tudies the side effec ead to other places in needed for cell gn e system in different . Condition	No Study Results Po the series of selar in the body and cannot b owth. Biological therapies to ways and stop tumor of	Intervention Disclair Disclair Disclair Disclair Disclair Disclair Disclair Disclair Disclair Disclair Disclair Disclair Disclair Disclair	n together v led with trea orine, use s Giving selu osporine	with cyclosporine in n atment. Selumetinib ubstances made fro metinib and cyclosp marker Analysis	treating pa may stop 1 m living of orine may	tients with solid he growth of th ganisms that n be a better trei Phase Phase	i tumors or co unor cells by nay stimulate atment for sol	olorectal blocking or id tumors
Harmation provided National Cancer Insi Full Text View Purpose This phase Vib brial 4 some of the enzyme or colorectal cancer	Tabular View Tabular View tudies the side effected to other places is needed for cell gris is expedien in different condition Recurrent Colorecta	No Study Results Po bis and best dose of selut in the biological therapiel towith. Biological therapiel toways and stop tumor of a Carcinoma	Insteid Disclair metinib when gives a cured or control s, such as cyclospi s, such as cyclospi s, such as cyclospi elis from growing. Intervention Drug: Cycl Other: Lat other: Pitt	n together v led with trea orine, use s Giving setur osportine poratory Bio partaologii	fow to result a development of the option of	treating pa may stop i mi living of orine may	tients with solid he growth of th ganisms that n be a better trei Phase Phase	t tumors or or mor cells by nay stimulate atment for sol	olorectal blocking or id tumors
Full Text View Full Text View Purpose This phase Vib Irial is some of the enzyme or colorectal cancer	Tabular View Tabular View tudies the side effec ead to other places is needed for cell gn e system in differen	No Study Results Po ots and best dose of selution in the body and cannot b work. Biological therapiet it ways and stop tumor or at Carcinoma at Cancer	Insteid Disclair metinib when gives a cured or control s, such as cyclospi ells from growing. I Intervention Drug: Cycl Other: Lat Other: Tab Drug: Sel	n together v led with trea orine, use s Giving setur osportine socratory Bio armacologia umetinib	fow to Head a development of the optication of the optical optication of the opticat	treating pa may stop 1 m living of orine may	tients with solid the growth of the ganisms that it be a better treat Phase Phase	t tumors or ci mor cells by nay stimulate atment for sol	olorectal blocking or id tumors
Full Text View Full Text F	Tabular View Tabular View tudies the side effected to cell gn se system in different. Condition Recurrent Colorecta Stage IIA Colorecta Stage IIA Colorecta	No Study Results Po 25 and best does of selut in the body and carrot but to ways and stop tumor of at ways and stop tumor of at Carcinoma at Cancer at Cancer	Intervention Disclair metinib when given ee cured or controll s, such as cyclaspi ets from growing. I Intervention Drug: Cycl Other: Phi Drug: Sek	n together v brind with treat orine, use as Giving seture osporine poratory Bio armacologi umetinib	fow to Heal a development of the option of t	treating pa may stop 1 m living of orine may	tients with solid the growth of the ganisms that in be a better treis Phase Phase	d tumors of of imore cells by any stimulate atment for sol	olorectal biocking or id tumons
Full Text View Pull Text View Pull Text View Pull Text View Compare that have say and the expresse the immun or colorectal cancer	Tabular View Tabular View tudies the side effet a needed to other places a needed for cell gn is system in differen Condition Recurrent Colorecta Stage IIIA Colorecta Stage IIIA Colorects Stage IIIB Colorect Stage IIIB Colorect	No Study Results Po ds and best done of selau in the body and carned b work. Bological therapele it ways and stop tumor or at Carcinoma al Canoer al Canoer al Canoer	Instead Disclair metinib when given a guida as cyclospi els from growing. I Intervention Drug: Cycl Other: Lat Other: Lat Drug: Selt	n together v ed with trea Giving selu osporine armacologi umetnib	fow to result a development of the second se	treating pa may stop i im living of orine may	tents with solid me growth of tr ganiams that n be a better tren Phase Phase	j tumors or or jmor cells by nay stimulate atment for sol	olorectal blocking or id tumons
Full Text View Full Text Full Text Full Text Full Text Full Full Text Full Text Full Text Full Text Full Text Full Text Full Full Text F	Tabular View Tabular View tudies the side effect and to other places is needed for cell gr is system in differen	No Study Results Po to and best done of solution work. Biological transport it ways and alog tumor or al Cancernia al Cancernia al Cancernia al Cancernia al Cancernia al Cancernia	Intervention Supervention Su	n together v led with trea orine, use s Giving setu osportine ooratory Bio armacologii umetinib	fow to result a development in internet. Seturation mathematical bucktances made from metinib and cyclospolarian and cyclospolarian for the seturation of th	treating pa may stop i m living of orine may	tents with solit ne growth of the gamisms that is to be a better treat Phase Phase	d tumors or co immor cells by adment for sol	blorectal blocking or id tumons
Internation provides Full Text View Pull Text View Purpose This chase View some of the enzyme or coloredial concer p	Tabular View Tabular View tudies the side effect ead to other places a needed for cell gn e system in differen	No Study Results Po the body and carshi in the body and carshi the body and carshi the body and carshi the body and carshi at carshi the Carcinoma at Cancer tal Cancer tal Cancer	Insted Disclair metinib when gives a cured or controll a, such as cyclospi els from growing. I Intervention Drug: Cycl Other: Lab Other: Phy Drug: Sel	n together v led with trea orine, use s Giving selu osportine orratory Bio oratory Bio oratory Bio oratorio Bio oratorio Bio oratorio Bio	fow to Head a development of Head a development of Head a development of the Head and Control of Head and	treating pa may stop to milving of orine may	tents with soli grantsmark of the ganisms that is be a better treat Phase Phase	tumors or or mor cells by stimulate timent for sol	otorectal blocking or id tumors
Internation provides National Cancel Insi Full Text View > Purpose This phase (up total at cancer that have spa- nergoes the set resum or colorectal cancer	Tabular View Tabular View tudies the side effec ead to other places a needed for cell gn expedient or cell gn expe	No Study Results Po to and best does of salari in the body and cannot b work. Biological therappe to ways and alog turnor of a Cancer al Cancer al Cancer ato Cancer ato Cancer ato Cancer	etted Disclair metinib when given e cured or controllor is, such as cyclospy also tren growing 1 Intervention Drug: Cycl Other: En Drug: Sel	n together v led with treat orine, use s Giving selu osporine ooratory Bio oratory Dio oratory Dio umetinib	vith cyclosporine in in atment. Seiumetenb uotances made fro metinb and cyclosp marker Analysis cal Study	treating pa may stop im living of onine may	benta with solit ine growth of te ganisms that n be a better tree Phase Phase	d tumors or or mor cells by any stimulate timent for sol	olorectal blocking or id lumons
Hermanian provident National Canner Inst Full Text View > Purpose This phase I/B trial is some of the enzyme or coloredial cancer Study Type:	Tabular View Tabular View Udes the side effect and to other places in needed for cell gn is needed for cell gn	No Study Results Po dis and best dose of selait in the body and cannot be own. Biological therapeet ways and sep tumor of all Canoor all Canoor ato Canoor ato Canoor ato Canoor ato Canoor	ated Disclarin metrinb when given a cured or control s, such as cyclospi lisk from growing. I Intervention Drug: Cycl Other: Lisk Other: Pin Drug: Sel	n together v led with tree orine, use s Giving setu osporine soratory Bio armacologii umetinib	vith cyclosporine in i hitment. Sokumetnik Jubatances made for metinib and cyclosp umarker Analysis. cal Shudy	treating pa may stop im living of onine may	tents with solit ne growth of tr ganiams that re be a better tren Phase Phase	d tumors of cl mor cells by nay stimulate atment for sol	olorectal blocking of all sumons
Internation provides International system International system International system International systems International sys	Tabular View Tabular View Luides the side effect and to other places in explane in artiferer service of the side of the service of the side of the Solid Neoplane Sales Neoplane Sales Neoplane Sales Neoplane Sales Neoplane Sales Neoplane Sales Neoplane Sales Neoplane Sales Neoplane	No Study Results Po March best done of selution in the body and cannob taken works. Biological therapies it ways and alop tumor co and cancer al C	ested Disclars meticilia when given e cured or controlling, such as controlling is uch as controlling of the output of the second of the Output of the Drug: Sea ant	n together v led with tree orine, use s Giving setu osporine osporine soratory Bio armacologi umetinib	for to read	treating pa may stop t im living of orine may	tents with solit ne growth of te ganisms that to be a better tree Phase Phase	d tumors or colle by nay stimulate atment for sol	slorectal blocking of us sumons sid sumons
Purpose Sudy Type: Sudy Type: Sudy Type:	Tabular View Tabular View Lucies the side effect and to other places needed for odip experiment condition Recorrent Conrect Stage IVE Colorect Stage IVE Colorect	No Study Results Po Mis and bast dose of selar to the boyont carrols to the selar thereares the selar thereares at Carcinoma to Cancer tal Cancer	ested Disclars method when given a cured or controlls, such as cyclosed alls from growing J Intervention Drug: Cycl Other: List Other: List Other: List Other: List	ner hogether v n together v ed with trea Giving selu a osporine armacologi umetinib	for to read	treating pa may stop 1 m living of orine may	tents with solid ne growth of te ganiams that it be a better tree Phase Phase (CsA) in Patie	d tumors or clils by may stimulate atment for sol	oloredal blocking of id tumons index solid
Vertication and the second statement of provident statement statement and the second statement of the	Tabular View Tabular View Tabular View Tabular View Tabular View Tabular View Tabular View Tabular Tab	No Study Results Po March Dest done of selut in the body and cancel back works. Biological theraper to ways and usop tumor co and cancer al Cancer	ested Disclars metchs when given a cord or control a, such as cyclose is from growing -1 letervention Other: Las Other: Las Other: Discussion Drug: Sel ant 2002/244 Hydrogen	ner hogether v ked with tres Giving seku a osporine armacologi umetinib	tox to reasult a white cyclospoortee in it substances made for metanical and cyclospoortee manufactor Analysis call Study adjunction and cyclospoortee manufactor and study adjunction and cyclospoortee manufactor and study adjunction and cyclospoortee adjunction adjunction	treating pa may stop on living of onne may	tents with solitone growth of te ganiams that it be a better tree Phase Phase (CsA) in Patie	d tumors of co imor cells by any stimulate atment for sol	olorectal blocking of al tumors unded Solid
Purpose Sudy Type: Sudy Type: Sudy Type:	Tabular View Tabular View Indias the side effect and to other plants needed for oding needed for oding needed for oding Name Needed Stage III Colored Stage III Colored Theorem Colored Stage III Colored Theorem Colored Stage III Colored Theorem Colored Stage III Colored Stage III Colored Stage III Colored Theorem Colored Stage III Colo	No Study Results Po as and best done of salut in the body and cannot be sales. Bodogal and salut is ways and sole lumor of a Cancer al Ca	ested Disclars method when given a cured or controlls, such as cyclogical less from growing J Indervention Order: Lip Drug: Cycl Order: Lip Drug: See anti-	n together v ed with trea orine, use a Giving selur asportine armacologii umetinib	fox to keep of the cyclosponine in it substances made the manaker Analysis and Study elements) and cyclosp	treating pa may stop i m living or onine may	tents with soliting growth of te ganisms that it be a better tree Phase Phase (CsA) in Patie	d tumors or colls by may stimulate atment for sol	olorectal blocking ad tumore

This year, we have developed and published several novel computational tools for translational bioinformatics and cancer systems biology research.

 DSigDB. Drug Signatures Database (DSigDB) is a new gene set resource that relates drugs/compounds and their target genes, for gene set enrichment analysis. DSigDB currently holds 22,527 gene sets, consists of 17,389 unique compounds covering 19,531 genes. We also developed an online DSigDB resource that allows users to search, view, and download drugs/compounds and gene sets. DSigDB gene sets provide seamless integration to GSEA software for linking gene expressions with drugs/compounds for drug repurposing and translational research. DSigDB is freely available for non-commercial use at http://tanlab.ucdenver.edu/DSigDB.

Reference: Yoo M*, Shin J*, Kim J, Ryall KA, Lee K, Lee S, Jeon M, Kang J, Tan AC. (2015). DSigDB: Drug Signatures Database for Gene Set Analysis. *Bioinformatics*. 31(18): 3069-3071. [PMID: 25990557].

Bardwaren (1916) (1915) 193 597 for 11 UB2-sectoremeter Adverter Kremt Paricus de UT WIT (1917) Adverter Kremt Paricus de UT WIT (1917)	DSigDB	Drug SIGnatures DataBase Collector of Averaged Drug / Compound Gene Seres	arch Gene Collection Browse Download Help
<section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header>	Segira Huma Harris Gana Salaction Sa	Browse Collection Bearch Dig08 : (a) 5://doi D1 Approved Drugs 1.202 gene sets D3 Perturbagen Signatures 1.998 gene sets	Search Refresh D2 Kinase Inhibitors 1,220 gene sets D4 Computational Drug Signatures 18,107 gene sets

Left: DSigDB paper published in Bioinformatics. Right: DSigDB web resource (http://tanlab.ucdenver.edu/DSigDB).

KAR. Kinase Addiction Ranker (KAR) is an algorithm that integrates high-throughput drug screening data, comprehensive kinase inhibition data and gene expression profiles to identify kinase dependency in cancer cells. KAR is available to download at: <u>http://tanlab.ucdenver.edu/KAR/</u>. We illustrated the integration of KAR and K-Map in dissecting kinase dependency and predicting drugs in triple negative breast cancer.

Reference: Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, Tan AC. (2015). Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. *Bioinformatics*. 31(23):3799-3806. [PMID: 26206305].

Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, Tan AC. (2015). An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. *BMC Genomics*. 16 (Suppl 12):S2. [PMID: 26681397].

Antonima IV (2017), 737 Stall All 1930 Double association Marrier Activity Patientine Star & Ark Stall United Patients Patientine Star & Ark Stall United Patients	New of the service and a service of the service of
<text><section-header><text><footnote><footnote><footnote><footnote><text><text><text><text></text></text></text></text></footnote></footnote></footnote></footnote></text></section-header></text>	Integrated Description An integrated bioinformatics analysis to dissect integrated bioinformatics analysis to dissect integrated bioinformatics analysis and bioinformatics analysis and bioinformatics analysis and bioinformatics and bioinformatics analysis and bioinformatics analysis and bioinformatic defense and bioinformatics analysis and bioinformatics and bioinformatic defense and bioinformatics analysis and bioinformatic defense and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinformatics and bioinform

Left: KAR paper published in Bioinformatics. Right: Integrating KAR and K-MAP for TNBC research.

TAN LAB – A REVIEW OF 2015

3 iCOSSY. COntext-Specific Subnetwork discoverY. COSSY is an algorithm to discover important subnetworks differentiating between two phenotypes (context). It automatically finds differentially expressed subnetworks of closely interacting molecules from molecular interaction networks (such as KEGG or STRING) using gene expression profiles. This is the first non-greedy approach of its kind. COSSY works for any interaction network regardless of the network topology. iCOSSY is a web server that finds subnetworks that are differentially expressed in two phenotypes, based on the concept of COSSY. Users can upload their gene discover expression datasets, and important subnetworks of closely interacting molecules to differentiate between two phenotypes (context). They can also interactively visualize the resulting subnetworks. iCOSSY can be accessed at: http://icossy.korea.ac.kr/.

Reference: Saha A, Jeon M, Tan AC, Kang J. (2015). iCOSSY: an online tool for context-specific subnetwork discovery from gene expression data. PLoS ONE. 10(7): e0131656. [PMID: 26147457].



We continued to contribute and collaborate with the **PETT** and **Messersmith** labs (colorectal cancer), **Jimeno** Lab (head and neck cancer), **DeGregori** Lab (cancer and aging), **Heasley** Lab (FGFR signaling), **Diamond** Lab (triple negative breast cancer), **Ford** Lab (SIX1/EMT), **Robinson** Lab (melanoma), **Schweppe** Lab (thyroid cancer), **Thorburn** lab (autophagy and cancer). We have established new collaboration with **Paul Huang** (**Institute of Cancer Research, London, UK**) in the understanding of kinase reprogramming in cancer as a resistance mechanism to targeted therapies. We continued to collaborate with Prof. **Jaewoo Kang** at the Korea University in developing new computational tools for extracting highly relevant and precise entity-relations from literature. We also continued to collaborate with Prof. **Sok Ching Cheong** at the Cancer Research Malaysia in identifying new druggable targets in oral cancer. We look forward to these exciting collaborations in the coming years!

Presentations: Our Cancer Center Summer Fellows, **Harrison** and **Ryan** presented their research at the annual fellows poster day. **Harrison** was working with **Karen Ryall** to systematically characterize the kinase-dependency in a large panel of cancer cell lines using Kinase Addiction Ranker (**KAR**). **Ryan** was working with **Jenn** to develop a web portal for integrating and visualizing melanoma genomics data. Congratulations to **Harrison** and **Ryan**!



Left: Karen, AC and Harrison with his poster. Right: Minjae, AC and Ryan with his poster.

AC has presented our research to several Korean universities (Korea University, Korea University Medical Center, Soongsil University, Sookmyung Women's University) as a visiting professor of the Korea University.

Karen presented the integration of KAR and K-Map paper at the the 1st Joint Conference of Genome Informatics Workshop (GIW) and International Conference on Bioinformatics (InCOB) in Tokyo, Japan. This is Karen's first trip to Asia, and she visited Korea University (Prof. **Jaewoo Kang**'s lab) en-route to Tokyo. **AC** also attended the conference and experienced the earthquake in Japan.



Left: Karen presenting at the GIW/InCOB 2015. Middle: Tokyo view from Odaiba. Right: Earthquake.

Grants and Funding: Jenn and **Karen** were awarded research grants from the Cancer League of Colorado. Following the tradition of the Tan lab, both of them have the chance to celebrate with a sparkling "juice". For the CLC project, Jenn will be researching the resistance mechanisms of drug combination in melanoma. Karen will be studying the kinome reprogramming in non-small cell lung cancer upon drug treatment. We thank the Cancer League of Colorado for their continuous supports to our research.



Left: Jenn getting some helps from Jaewoo and Bryan in opening up her bottle, first-timer. *Right*: Karen is very careful in opening up her bottle.

AC and **Paul Huang** received an international exchange grant from the Royal Society to initiate collaborative research between our labs. We would like to congratulate to our valuable collaborators on securing new grants this past year: **Scott Cramer** (R21), **Stephen Malkoski** (R21), and **Andrew Thorburn** (R01). We will continue to write and submit proposals for this coming year! We also like to acknowledge the generous support from the David F. and Margaret T. Grohne Family Foundation to our research. Thank you for supporting our research!

Publications: This past year, we have published 20 papers. According to Google Scholar, we have accrued more than 800 citations in 2015 related to the publications of our lab. We look forward for another productive year! Go Tan Lab!

- Song EK, Tai W, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, <u>Wang G^{*}</u>, Blatchford P, Yahn R, Kaplan J, **Tan AC**, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. (2015). Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. *International Journal of Cancer*. 136(8):1967-1975. [PMID: 25242168]. [PMCID: PMC4323738]
- Micel LN, Tentler JJ, Tan AC, <u>Selby HM</u>⁺, Brunkow KL, Robertson KM, Davis SL, <u>Klauck PJ</u>⁺, Pitts TM, Gangolli E, Fabrey R, O'Connell SM, Vincent PW, Eckhardt SG. (2015). Antitumor Activity of the MEK Inhibitor TAK-733 Against Melanoma Cell Lines and Patient-Derived Tumor Explants. *Molecular Cancer Therapeutics*. 14(2): 317-325. [PMID: 25376610].
- Fleenor CJ, Rozhok AI, Zaberezhnyy V, Mathew D, <u>Kim J⁺</u>, Tan AC, Bernstein ID, DeGregori J. (2015). Contrasting Roles for C/EBPalpha and Notch in Irradiation-Induced Multipotent Hematopoietic Progenitor Cell Defects. *Stem Cells.* 33(4):1345-1358. [PMID: 25546133]. [PMCID: PMC4376650]
- Petillo D, Orey S, Tan AC, Forsgren L, Khoo SK. (2015). Parkinson's Disease-related Circulating microRNA Biomarkers a Validation Study. *AIMS Medical Science*. 2(1): 7-14.
- <u>Ryall KA⁺</u>, Tan AC. (2015). Systems Biology Approaches For Advancing The Discovery Of Effective Drug Combinations. *J. Cheminformatics*. 7:7. [PMID: 25741385]. [PMCID: PMC4348553][*Highly Accessed Article*]
- Drasin DJ, Guarnier AL, Neelakantan D, <u>Kim J⁺</u>, Cabrera JH, Wang CA, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, **Tan AC**, Ford HL. (2015). Twist1-induced microRNA-424 reversibly drives mesenchymal programming while inhibiting tumor initiation. *Cancer Research* 75(9): 1908-1921. [PMID: 25716682]. [PMCID: PMC4417413]
- Tentler JJ, Ionkina A, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JD. (2015). p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. *Molecular Cancer Therapeutics*. 4(5):1117-1129. [PMID: 25758253]. [PMCID: PMC4425647]
- Kleczko EK, <u>Kim J⁺</u>, Keysar SB, Heasley LR, Eagles-Soukup J, Simon M, Marshall ME, Singleton KR, Jimeno A, **Tan AC**, Heasley LE. (2015). An Inducible TGFB2-TGFBR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinases Inhibitors Targeting Dominant Receptor Tyrosine Kinases. *PLoS ONE*. 10(5):e0123600. [PMID: 25946135]. [PMCID: PMC4422719].
- Yonekawa T, Gamez G, <u>Kim J</u>⁺, **Tan AC**, Thorburn J, Gump J, Thorburn A, Morgan MJ. (2015). RIP1 Negatively Regulates Basal Autophagic Flux through TFEB to Control Sensitivity to Apoptosis. *EMBO Reports*. 16:700-708. [Epub ahead of print, Apr 23, 2015] [PMID: 25908842].
- <u>Yoo M⁺*</u>, <u>Shin J⁺</u>, <u>Kim J⁺</u>, <u>Ryall KA⁺</u>, Lee K, Lee S, Jeon M, Kang J, **Tan AC**. (2015). DSigDB: Drug Signatures Database for Gene Set Analysis. *Bioinformatics*. 31(18):3069-3071. [PMID: 25990557].

- Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Mäessenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schröck A, <u>Kim J⁺</u>, **Tan** AC, Jimeno A, Heasley LE, Perner S. (2015). FGFR1 expression levels predict BGJ398-sensitivity of FGFR1dependent head and neck squamous cell cancers. *Clinical Cancer Research*. 21(19): 4356-4364. [PMID: 26015511].
- Davis EM, <u>Kim J</u>⁺, Menasche B, Sheppard J, Liu X, **Tan AC**, Shen J. (2015). Comparative haploid genetic screens reveal divergent pathways in the biogenesis of glycophosphatidylinositol-anchored proteins. *Cell Reports*. 11(11):1727-1736. [PMID: 26074080].
- Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, <u>Klauck PJ⁺</u>, Bagby SM, Hyatt SL, <u>Selby HM⁺</u>, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, **Tan AC**, Eckhardt SG. (2015). Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. *Frontiers in Pharmacology*. 6:120. [PMID: 26136684].
- Saha A, Jeon M, Tan AC, Kang J. (2015). iCOSSY: an online tool for context-specific subnetwork discovery from gene expression data. *PLoS ONE*. 10(7): e0131656. [PMID: 26147457].
- <u>Ryall KA⁺, Kim J⁺, Klauck PJ⁺, Shin J⁺, Yoo M⁺, Ionkina A, Pitts</u> TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, **Tan AC**. (2015). An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. *BMC Genomics*. 16 (Suppl 12):S2. [PMID: 26681397].
- <u>Ryall KA⁺, Shin J⁺, Yoo M⁺, Hinz TK, Kim J⁺, Kang J, Heasley LE, Tan AC. (2015). Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. *Bioinformatics*. 31(23):3799-3806. [PMID: 26206305].
 </u>
- Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, <u>Kim J⁺</u>, **Tan AC**, Heasley LE. (2015). Kinome RNAi Screens Reveal Synergistic Targeting of mTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. *Cancer Research*. 75(20): 4398-4406. [PMID: 26359452].
- Lieu CH, <u>Klauck PJ</u>⁺, Henthron PK, Tentler JJ, **Tan AC**, Spreafico A, <u>Selby HM</u>⁺, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG. (2015). Antitumor Activity of a Potent MEK Inhibitor, TAK-733, Against Colorectal Cancer Cell Lines and Patient Derived Xenografts. *Oncotarget*. 6(33):34561-34572. [PMID: 26439693].
- Henry C, Casas-Selves M, <u>Kim J</u>⁺, Zaberezhnvv V, Aghili L, Daniel A, Jimenez L, Azam T, McNamee EN, Clambey E, Klawitter J, Serkova N, **Tan AC**, Dinarello C, DeGregori J. (2015). Aging-associated inflammation promotes selection for adaptive oncogenic events in B-progenitors. *The Journal of Clinical Investigation*. 125(12):4666-4680. [PMID: 26551682].
- Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, <u>Kim J⁺</u>, Wang CA, Oliphant MUJ, Drasin DJ, Guney MA, Kabos P, Sartorius CA, **Tan AC**, Perou CM, Espinosa JM, Ford HL. (2015). The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27-a-3p. *Nature Communications*. 6:10077. [PMID: 26687066].

Lab Social Activities and Celebrations: Dim sum lunch to celebrate the acceptance of DSigDB in *Bioinformatics*.



Left: Group picture, Cheers! Right: Dim sum, yummy!

Sushi dinner to celebrate the acceptance of two KAR papers: KAR method (*Bioinformatics*) and its applications in triple negative breast cancer (*BMC Genomics*). Karen presented the TNBC paper in the 1st Joint Conference of Genome Informatics Workshop (GIW) and International Conference on Bioinformatics (InCOB) in Tokyo, Japan.



Left: Karen and Jimin. Middle: Sushill Right: Group picture, Cheers!

We also hosted farewell parties for: Kyubum (Mexican foods in Feb), Dr. Shin (Korea BBQ in June) and Minji (American BBQ in August).

Baby: Minjae and Jimin welcome their first baby boy Jeremy Junho Yoo in Sept 2015, Congratulations Minjae and Jimin!





With some good science in the works and the great collaborations with our colleagues, I am sure that 2016 will be another exciting and good year for the lab. Thank you all for your hard work and I look forward to working together with you in the year ahead.

Aik Choon Tan, Ph.D. Associate Professor Director, Translational Bioinformatics and Cancer Systems Biology Lab December 30, 2015.



We only focus on the research that matters! The Tan Lab will continue to address challenging problems in cancer research by harnessing the power of big data and developing novel and innovative computational methods.

Support Our Research and Contact Us

Aik Choon Tan, Ph.D. Associate Professor of Bioinformatics Translational Bioinformatics and Cancer Systems Biology Laboratory Program for the Evaluation of Targeted Therapy Division of Medical Oncology, Department of Medicine, School of Medicine University of Colorado Anschutz Medical Campus Mail Stop 8117 12801 E.17th Ave., L18-8116 Aurora CO 80045 Tel: 303.724.2520 Fax: 303.724.3889 Email: AikChoon.Tan@UCDenver.edu Web: http://tanlab.ucdenver.edu